89489-26-9

Usage

Uses

Used in Pharmaceutical Industry:
Bicyclo[3.1.0]hexan-3-ol is used as a reagent for the preparation of cycloalkoxyadenosines, which are bacterial NAD+ dependent DNA ligase inhibitors. These inhibitors play a crucial role in the development of new antibiotics and antimicrobial agents, as they can effectively target and inhibit the activity of bacterial DNA ligases, thereby disrupting the replication and repair mechanisms of bacteria.
In the context of antibiotic resistance, which is a growing global health concern, the development of novel inhibitors like cycloalkoxyadenosines can provide alternative treatment options and help combat resistant bacterial strains. By using Bicyclo[3.1.0]hexan-3-ol as a key reagent in the synthesis of these inhibitors, researchers can explore new avenues for creating effective antimicrobial drugs and addressing the challenges posed by antibiotic resistance.

Upstream product

• 75-11-6 diiodomethane 
• 14320-38-8 cyclopent-3-enol 
• 285-58-5 bicyclo[3.1.0]hexane 
• 285-58-5 bicyclo<3.1.0>hexane 
• 1755-04-0 bicyclo[3.1.0]hexan-3-one 
• 694-43-9 (1R,3r,5S)-bicyclo[3.1.0]hexan-3-ol 
• 1755-04-0 bicyclo[3.1.0]hexan-3-one 

Downstream Products

• 832-09-7 (1R^*,3S^*)-1,3-cyclohexanediol diacetate 
• 694-44-0 trans-bicyclo<3.1.0>hexan-3-ol 
• 1284249-22-4 (trans)-bicyclo[3.1.0]hex-3-ylamine hydrochloride 
• 79531-79-6 trans-3-Amino-bicyclo<3,1,0>hexan 

Relevant academic research and scientific papers

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I.

RET Inhibitor. Pharmaceutical composition and use thereof

The invention belongs to the field of medicines, and relates to RET inhibitor, a pharmaceutical composition and application thereof. , The present invention relates to a compound represented by formula (I), a stereoisomer, a tautomer, an oxynitride, a solvate, a metabolite, a pharmaceutically acceptable salt or prodrug thereof, I, and a pharmaceutical composition thereof in the manufacture of a medicament, in particular for the treatment and prophylaxis of diseases and disorders associated and RET.

N-SUBSTITUTED-4-OXO-3,4-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth Formula I.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.

N-SUBSTUTUTED-6-OXO-1,6-DIHYDROPYRIMIDINE-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

A compound of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: (I)

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: (I)

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

A pharmaceutical composition comprising the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof, is set forth. (Formula Ia), (Formula Ib), (Formula Ic), (Formula Id)

QUINAZOLINYL-INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula (I):

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of Formula (I), including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.